妊娠中期接种BNT162b2疫苗后分娩时母儿SARS-CoV-2 IgG抗体水平
这项前瞻性队列研究在以色列海法单中心纳入129名妊娠中期完成两剂BNT162b2疫苗、无既往感染的孕妇,分娩时母体与脐带血SARS-CoV-2 IgG检测全部阳性。新生儿IgG中位滴度为母体的2.6倍,母儿抗体正相关(r=0.92),距第二剂时间越长及母亲年龄越大,抗体水平越低。
要点
- 妊娠中期接种BNT162b2后,分娩时母体与脐带血IgG检测100%阳性。
- 新生儿IgG中位滴度3315.7 AU/mL,为母体1185.2 AU/mL的2.6倍。
- 距第二剂每过1周,母体与新生儿抗体分别下降10.9%和11.7%。
核心结论
- 妊娠中期接种BNT162b2 mRNA新冠疫苗与分娩时母体和新生儿体液免疫应答相关,支持孕期接种以同时实现母体保护与新生儿安全。
研究设计与样本
- 前瞻性队列研究,以色列海法单中心,2021年5月至7月开展。
- 纳入129名单胎妊娠超过24周、接种第二剂至少7天且无既往新冠感染史的孕妇,并检测114名新生儿的抗体。
主要发现
- 129名孕妇(平均年龄31.9岁,SD 4.9)与114名新生儿的抗体检测结果100%为阳性。
- 第二剂接种平均孕周为24.9周(SD 3.3)。
- 母体与新生儿抗体呈正相关(r=0.92;95%CI 0.89-0.94)。
关键数值与推荐
- 距第二剂每过1周,母体抗体变化-10.9%(95%CI -17.2%至-4.2%;P=.002),新生儿抗体变化-11.7%(95%CI -19.0至-3.8;P=.005)。
- 母亲年龄每增加1岁,母体抗体变化-3.1%(95%CI -5.3%至-0.9%;P=.007),新生儿抗体变化-2.7%(95%CI -5.2%至-0.1%;P=.04)。
临床怎么用
- 提示妊娠中期接种BNT162b2可使新生儿获得高于母体的IgG滴度,可作为孕期接种咨询依据。
- 接种后间隔时间延长与母亲年龄较大均与抗体水平下降相关,评估保护窗口时可参考。
局限性
- 单中心小样本队列,仅观察至分娩时抗体水平,未报告临床保护效力数据。
- 研究限于BNT162b2、妊娠中期接种且无既往感染者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: BNT162b2 messenger RNA (mRNA) COVID-19 vaccination in the third trimester was found to be associated with a strong maternal humoral IgG response that crossed the placenta and approached maternal titers in the newborn. OBJECTIVE: To evaluate maternal and neonatal SARS-CoV-2 immunoglobulin G (IgG) antibody levels at birth after mRNA COVID-19 vaccination during the second trimester of pregnancy. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study, conducted at a single medical center in Haifa, Israel, from May to July 2021, included women with a singleton pregnancy over 24 weeks of gestation at least 7 days after receipt of their second COVID-19 vaccine dose who were not known to be previously infected with COVID-19. EXPOSURES: BNT162b2 (Pfizer/BioNTech) vaccination. MAIN OUTCOMES AND MEASURES: The primary outcomes were SARS-CoV-2 IgG antibody titers measured in the parturient at admission and in the umbilical cord blood within 30 minutes after delivery. Secondary outcomes were the correlation between antibody titers, feto-maternal characteristics, maternal adverse effects after vaccination, and time interval from vaccination to delivery. RESULTS: Antibody levels were measured for 129 women (mean [SD] age, 31.9 [4.9] years) and 114 neonates, with 100% of the tests having positive results. The mean (SD) gestational age at administration of the second vaccine dose was 24.9 (3.3) weeks. Neonatal IgG titers were 2.6 times higher than maternal titers (median [range], 3315.7 [350.1-17 643.5] AU/mL vs 1185.2 [146.6-32 415.1] AU/mL). A positive correlation was demonstrated between maternal and neonatal antibodies (r = 0.92; 95% CI, 0.89-0.94). Multivariable analysis revealed that for each week that passed since receipt of the second vaccine dose, maternal and neonatal antibody levels changed by -10.9% (95% CI, -17.2% to -4.2%; P = .002) and -11.7% (95% CI, -19.0 to -3.8%; P = .005), respectively. For each 1-year increase in the mother's age, maternal and neonatal antibody levels changed by -3.1% (95% CI, -5.3% to -0.9%; P = .007) and -2.7% (95% CI, -5.2% to -0.1%; P = .04), respectively. CONCLUSIONS AND RELEVANCE: In this cohort study, receipt of the BNT162b2 mRNA COVID-19 vaccine during the second trimester of pregnancy was associated with maternal and neonatal humoral responses, as reflected in maternal and neonatal SARS-CoV-2 IgG antibody levels measured after delivery. These findings support COVID-19 vaccination of pregnant individuals during the second trimester to achieve maternal protection and newborn safety during the pandemic.
引用
- Kugelman N, Nahshon C, Shaked-Mishan P, et al. Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy. JAMA Pediatr. 2022. PMID: 34932066. doi:10.1001/jamapediatrics.2021.5683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。